Alyatec
Alyatec is a Strasbourg-based clinical research organization (CRO) operating France's only next-generation environmental exposure chamber, running standardized, year-round allergy and respiratory clinical trials for pharmaceutical, medical device, consumer health, and academic sponsors.
- Company typePrivate
- Founded2014
- HeadquartersStrasbourg, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Alyatec does
Alyatec is a private, France-based contract research organization (CRO) and clinical research center headquartered at Nouvel Hôpital Civil in Strasbourg, founded in 2013-2014 and operational since 2016. The company specializes in clinical trials for respiratory allergies, allergic conjunctivitis, asthma, and related environmental diseases, serving pharmaceutical companies (Regeneron, Stallergenes Greer, Laboratoires Théa), medical device manufacturers (Medicom), consumer health and home appliance brands (Dyson, Groupe SEB/Rowenta, Laboratoires SVR), diagnostics developers (DiagnosTear), and academic/government research institutions (AP-HP, Université de Bâle, CHU UCL Namur). Its core asset is a next-generation environmental exposure chamber (EEC) — a 65 m² facility with 20 patient chairs that delivers standardized, reproducible, year-round allergen exposure (cat, pollen, dust mites) independent of natural seasonal conditions.
Alyatec's service offering spans the full CRO workflow: custom protocol design, regulatory and ethics submissions, patient recruitment from a database of more than 2,000 pre-characterized allergic volunteers, biological sample collection, data management (supported by partner Soladis), clinical report writing, and scientific publication. The company has completed over 26 clinical studies since 2016 and is currently running multiple trials across respiratory, dermatology, and diagnostic indications. Revenue is generated on a professional services basis via per-study contracts with enterprise sponsors; pricing for volunteer participation is separately disclosed (€0-300 per visit, capped at €6,000 annually per volunteer) but is not the company's commercial pricing.
The business is led by Professor Frédéric de Blay (President, key opinion leader in allergology) and a small core team of approximately 8 employees including clinical operations, allergist physicians, a clinical research nurse, a laboratory technician, and a business development officer. Alyatec is structured as a French S.A.S., was initially financed in 2015 by a consortium of public (BPI France, Eurométropole de Strasbourg, Caisse des Dépôts, Région Alsace, SODIV) and private (founders, BNP Paribas, Crédit Mutuel, SHAM) backers, and has received regional innovation awards plus EAACI scientific recognition in 2018 and 2024.
Alyatec firmographics
Firmographics- Name
- Alyatec
- Legal name
- ALYATEC S.A.S.
- Website
- https://alyatec.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Alyatec is a Strasbourg-based clinical research organization (CRO) operating France's only next-generation environmental exposure chamber, running standardized, year-round allergy and respiratory clinical trials for pharmaceutical, medical device, consumer health, and academic sponsors.
- Ownership category
- akta.pro rank
Alyatec industry classification
Industry- Product category
- Contract Research Organization (Clinical Research Services)
- NAICS
- Testing Laboratories and Services (54138), Professional, Scientific, and Technical Services (541)
- SIC
- Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industry
- Occupational Exposure Laboratory Services (Analytical Testing & Chain-of-Custody) (EUAHAGAL)
Keywords
Where Alyatec is headquartered
LocationHeadquarters
- HQ city
- Strasbourg
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Alyatec business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Research Services: ALYATEC generates revenue as a contract research organization (CRO) and clinical research center by conducting clinical trials for pharmaceutical companies, medical device manufacturers, and academic institutions. Services include study design, protocol creation, patient recruitment, exposure chamber trials, data collection and analysis, and clinical report writing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One-time | Registration visit - Uncompensated |
| Other | One-time | Selection visit - €30-100 |
| Other | Per visit | Study visits - €30-200 |
| Other | Per visit | Exposure chamber days - €150-300 |
| Other | Per visit | PALPEBRAL study compensation |
| Other | Per study | DIA-001 study compensation |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Alyatec product offering
Product offeringCore offering
Alyatec is a contract research organization (CRO) and clinical research center that runs allergy and respiratory disease clinical trials for pharmaceutical, medical device, consumer product, and academic clients. Its core asset is the next-generation Environmental Exposure Chamber (EEC), a 65 m² controlled facility with 20 patient chairs that enables standardized, reproducible allergen exposure studies (cat, pollen, dust mites, food) independent of natural seasonal conditions. Services span protocol design, regulatory/ethics submissions, patient recruitment from a 2,000+ volunteer database, biological sample collection, data management, and clinical report writing for Phase 1–4 trials in children and adults.
Product overview
Alyatec is a contract research organization (CRO) and clinical research center offering a suite of services centered on its next-generation Environmental Exposure Chamber (EEC). The EEC is a 65 m² controlled-environment facility enabling standardized allergen exposure studies for asthma, rhinitis, and conjunctivitis year-round. Alyatec's clinical study services encompass protocol design, regulatory submissions, patient recruitment, biomarker sample collection, data management, and clinical report writing, supporting evaluation of pharmaceutical products, medical devices, air purifiers, dietary supplements, dermo-cosmetic products, and protective masks. The company operates exclusively from its Strasbourg facility and has conducted over 20 clinical trials since 2016 for pharmaceutical companies, medical device manufacturers, and academic partners.
Differentiator
Problem solved
Functional benefit
Products and services
- Environmental Exposure Chamber (EEC) A next-generation environmental exposure chamber (approximately 65 m² with 20 seats) that enables standardized, controlled, and reproducible allergen exposure for clinical trials, allowing year-round allergen challenge studies independent of natural pollen seasons. The chamber controls temperature, air renewal, and atmospheric pressure, and can recreate normal environmental quantities of allergens such as cat, pollen, and dust mites. Sold to enterprise clients (pharmaceutical, medical device, consumer product, and academic) as a study site facility.
- Clinical Study Services (CRO Services) Full-service contract research organization (CRO) clinical study services in allergy and respiratory diseases. Includes custom protocol development, health authority and ethics committee submissions, patient recruitment from a 2,000+ volunteer database, exposure chamber trials, biological sample collection, data management and analysis, clinical report writing, and scientific/medical consulting for Phase 1-4 trials in children and adults. Sold to pharmaceutical companies, medical device manufacturers, consumer product firms, dermocosmetic brands, and academic institutions.
Quantifiable outcome
- Reduced clinical trial timelines with smaller cohorts compared to field studies
- +1 more outcomes
Companies that use Alyatec
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles4 records
Alyatec technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Alyatec partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, minor and major.
- Stallergenes GreercoreResearch collaboration announced July 2021 to advance precision medicine in allergen immunotherapy (AIT). Stallergenes Greer, a global healthcare company specializing in allergen immunotherapy, partnered with ALYATEC to leverage their expertise in AIT and ALYATEC's clinical research capabilities and environmental exposure chamber technology.
- SoladisminorSoladis Group, specializing in data management and analysis, supports ALYATEC in exploiting clinical data collected during studies.
- Regeneron PharmaceuticalscoreMultiple clinical studies conducted for Regeneron, including Phase 2 study evaluating REGN1908-1909 monoclonal antibodies for cat-allergic asthma. 56 patients enrolled and exposed to cat allergen in ALYATEC's environmental exposure chamber. Results published in Journal of Allergy and Clinical Immunology.
- Laboratoires ThéamajorClinical study comparing efficacy of NAABAK vs FLUCON eye drops for allergic conjunctivitis in birch pollen allergic patients. Results published in Clinical & Experimental Allergy.
- DysonmajorClinical study evaluating efficacy of Dyson air purifiers for cat-allergic asthma patients. Results published in Respiratory Medicine 2025 showing significant reduction in asthma and rhinoconjunctivitis symptoms.
- Groupe SEB (Rowenta)majorClinical study evaluating efficacy of SEB-Rowenta air purifiers for cat-allergic asthma patients. Published in Clinical & Experimental Allergy 2019.
- Medicom (Kolmi Hopen)minorClinical study evaluating efficacy of KOLMI OP-Air medical masks in reducing asthma and rhinitis symptoms in birch pollen allergic patients. Published in Revue Française d'Allergologie 2022.
- Assistance Publique des Hôpitaux de Paris (AP-HP)majorRHINIL-2 clinical study on safety and efficacy of low-dose anti-IL2 for birch pollen allergic rhinitis. Results published in Journal of Allergy and Clinical Immunology 2024.
- Université de BâleminorAcademic collaboration (BAS-001 study) evaluating asthmatic responses in patients exposed to house dust mites allergens.
- CHU UCL Namur / Université Catholique de LouvainminorAcademic collaboration led by Dr. Virginie Doyen evaluating early and late asthmatic responses in mite-allergic patients. Results published in Allergy journal 2023.
- DiagnosTearmajorDIA-001 clinical study launched February 2026 collecting tears from cat-allergic patients during conjunctival provocation tests to validate TeaRx Red Eye immunological detection kit for allergic conjunctivitis diagnosis.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Alyatec competitors and assessment
Company assessmentDirect peers
- Inflamax Research (now part of Cliantha Research): Canadian-headquartered CRO that operates environmental exposure chambers (Toronto/Mississauga) for allergen challenge clinical trials — the closest direct competitor to Alyatec in EEC-based allergy trial services.
- Celerion: Early-phase clinical research organization with established allergen challenge and respiratory trial capabilities serving global pharma, comparable to Alyatec's Phase 1/early Phase 2 offering.
- Worldwide Clinical Trials: Mid-size specialty CRO with strong respiratory and immunology therapeutic expertise and a comparable profile of mid-sized pharma/biotech sponsors.
Broad incumbents
- Charles River Laboratories: Major early-phase contract research organization with safety assessment and clinical capabilities that touches similar biotech/specialty pharma clients across respiratory indications.
- ICON plc: One of the world's largest CROs with broad respiratory and allergy capabilities across multiple continents — would compete with Alyatec if it added or partnered for EEC capacity.
- PPD (Thermo Fisher Scientific): Large global CRO within Thermo Fisher, covering early- through late-stage clinical development across respiratory and immunology indications relevant to Alyatec's sponsors.
- Parexel International: Global full-service CRO with therapeutic experience in allergy/immunology and a sponsor base overlapping with Alyatec's enterprise clients (e.g., Regeneron, Stallergenes Greer-equivalents).
- IQVIA: Global CRO with deep pharma relationships and dedicated respiratory/immunology therapeutic teams; represents the type of incumbent that could bundle EEC services at scale.
Others
- SGS Life Sciences: Global testing, inspection, and certification company with clinical and bioanalytical lab services — an ecosystem peer offering adjacent lab/testing capabilities to EEC CROs like Alyatec.
- Eurofins Scientific: International testing laboratory group with bioanalytical and clinical laboratory services supporting allergy and respiratory clinical trials — an adjacent/ecosystem peer supplying testing rather than competing for the same EEC niche.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Alyatec social profiles
Digital presenceAlyatec financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alyatec leadership team
Management profileNumber of profiles
Profiles7 records
Alyatec funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alyatec M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alyatec
What does Alyatec do?
Alyatec is a contract research organization (CRO) and clinical research center that runs allergy and respiratory disease clinical trials for pharmaceutical, medical device, consumer product, and academic clients. Its core asset is the next-generation Environmental Exposure Chamber (EEC), a 65 m² controlled facility with 20 patient chairs that enables standardized, reproducible allergen exposure studies (cat, pollen, dust mites, food) independent of natural seasonal conditions. Services span protocol design, regulatory/ethics submissions, patient recruitment from a 2,000+ volunteer database, biological sample collection, data management, and clinical report writing for Phase 1–4 trials in children and adults.
Is Alyatec a public or private company?
Alyatec is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Alyatec founded?
Alyatec was founded in 2014. It employs 1 to 10 people.
Where is Alyatec based?
Alyatec is headquartered in Strasbourg, France, in the Europe region.
How does Alyatec make money?
One revenue line is on record: contract Research Services.
Who are Alyatec's main competitors?
Direct peers on record are Inflamax Research (now part of Cliantha Research), Celerion and Worldwide Clinical Trials. Broad incumbents are Charles River Laboratories, ICON plc, PPD (Thermo Fisher Scientific), Parexel International and IQVIA. Others are SGS Life Sciences and Eurofins Scientific.
Does Alyatec have an API?
No public API is recorded for Alyatec.
What industry is Alyatec in?
Alyatec's product category is Contract Research Organization (Clinical Research Services). Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of EUAHAGAL, Occupational Exposure Laboratory Services (Analytical Testing & Chain-of-Custody). Its NAICS code is 54138 and its SIC code is 8734.